Ney Carter Borges: Endothelial Senescence as a Central Driver of Adipose Dysfunction in Heart Failure and Type 2 Diabetes
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Endothelial Senescence as a Central Driver of Adipose Dysfunction in Heart Failure and Type 2 Diabetes:
Therapeutic Implications of Senolytic Targeting
This translational study investigates the role of endothelial senescence in subcutaneous adipose tissue (SAT) dysfunction among patients with heart failure and type 2 diabetes (HFDM).
Using human SAT biopsies, the authors demonstrate that microvascular endothelial cells (MVECs) from HFDM patients exhibit a clear senescent phenotype, characterized by increased senescence-associated β-galactosidase activity, reduced proliferative and angiogenic capacity, mitochondrial dysfunction, and a proinflammatory secretory profile (SASP).
Functionally, these senescent endothelial cells drive maladaptive cross-talk with adipocytes.
In coculture experiments, they induce a proinflammatory adipocyte phenotype marked by increased interleukin-6 expression, reduced adiponectin, impaired GLUT4 expression, and decreased glucose uptake—key features of metabolic dysfunction.
This establishes endothelial senescence as a central mechanistic link between vascular dysfunction and impaired adipose metabolic regulation in HFDM.
Importantly, the study identifies digoxin, at therapeutic concentrations, as a potential senolytic agent.
Treatment with digoxin significantly reduced endothelial senescence markers, improved mitochondrial function and proliferation, and attenuated inflammatory cytokine secretion.
Consequently, adipocytes exposed to digoxin-treated endothelial cells demonstrated improved glucose uptake and a more favorable metabolic phenotype.
These findings introduce a novel paradigm in cardiometabolic disease:
Endothelial senescence is not merely a bystander but an active driver of adipose tissue dysfunction.
Therapeutically targeting senescent endothelial cells may therefore represent a promising strategy to restore metabolic homeostasis in high-risk HFDM populations.
However, clinical translation requires caution given digoxin’s narrow therapeutic window and the need for in vivo validation.
Overall, this study provides strong mechanistic insight and opens new avenues for senescence-targeted therapies in cardiometabolic disease.”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
Jul 30, 2026, 18:36Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
-
Jul 30, 2026, 18:11Tobias Tritschler: Evaluating Timing, Translation and Preparedness in COVID-19 Anticoagulation Management
-
Jul 30, 2026, 16:05Peter Zdziarski: Today is Chronic Disease Awareness Day
-
Jul 30, 2026, 15:50Ahmad Gharehbaghian: New Blood Transfusion Centers Open in Iran
-
Jul 30, 2026, 15:32Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal
-
Jul 30, 2026, 15:162025 Platelet Transfusion Thresholds: When to Transfuse and When Not to Transfuse – Chokri Ben Lamine
-
Jul 30, 2026, 14:34Flora Peyvandi: Genetics of Early-Onset Coronary Artery Disease in Iranians
-
Jul 30, 2026, 14:22Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
-
Jul 30, 2026, 14:09Hilal Ahmad: New Guidelines for Pediatric Ischemic Stroke Management